Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccine Development
P40 Adjuvant Has Potential For Anti-Tumor Vaccine
April 11th, 2001
N.R. Saltmarsh, staff medical writer - A Klebsiella pneumoniae membrane protein appears to be a useful adjuvant for immune stimulation with peptide vaccines, say researchers working in France. I. Miconnet and colleagues at the University of Lausanne noted that the potential of tumor antigens as vaccines has encouraged a search for efficient adjuvants and delivery systems, especially for peptide-based vaccinations. "We investigated the adjuvant potential of the recombinant 40-kDa outer membrane protein of Klebsellia pneumoniae (P40) for specific CTL induction," reported Miconnet and team. They combined P40 with two...
Source: Vaccine Weekly (2001-04-11)
|
